Top Analyst Reports for Berkshire Hathaway, JPMorgan & Procter & Gamble
Berkshire Hathaway, JPMorgan and Procter & Gamble benefit from strong business fundamentals, but rising costs and growth challenges create risks.
Read more
Historical closes from the market data provider. Adjusted for splits; corporate actions can affect comparability across periods.
Metrics supplied by the company data provider. Trailing-twelve-month figures update when the provider refreshes its dataset.
Fiscal years 2023, 2024, 2025, 2026. All figures in USD. Values are as reported by the company.
| Line item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total revenue | $82.01B | $84.04B | $84.28B | $87.03B |
| Gross profit | $39.25B | $43.19B | $43.12B | $43.67B |
| Operating income | $18.13B | $19.89B | $20.45B | $19.75B |
| Net income | $14.65B | $14.88B | $15.97B | $16.05B |
| Diluted EPS | 5.90 | 6.02 | 6.51 | 6.62 |
| Total assets | $120.83B | $122.37B | $125.23B | $126.52B |
| Shareholders' equity | $46.78B | $50.29B | $52.01B | $54.08B |
| Operating cash flow | $16.85B | $19.85B | $17.82B | $19.56B |
| Free cash flow | $13.79B | $16.52B | $14.04B | $15.15B |
Annual statements sourced from the market data provider. Companies with different fiscal year ends are not directly comparable on a calendar basis.
| Ex-date | Amount per share |
|---|---|
| 23 Oct 2026 | $1.0890 |
| 24 Jul 2026 | $1.0890 |
| 24 Apr 2026 | $1.0890 |
| 23 Jan 2026 | $1.0570 |
| 24 Oct 2025 | $1.0570 |
| 18 Jul 2025 | $1.0570 |
| 21 Apr 2025 | $1.0570 |
| 24 Jan 2025 | $1.0070 |
| 18 Oct 2024 | $1.0070 |
| 19 Jul 2024 | $1.0070 |
| 18 Apr 2024 | $1.0070 |
| 18 Jan 2024 | $0.9410 |
| 19 Oct 2023 | $0.9410 |
| 20 Jul 2023 | $0.9410 |
| 20 Apr 2023 | $0.9410 |
| 19 Jan 2023 | $0.9130 |
| 20 Oct 2022 | $0.9130 |
| 21 Jul 2022 | $0.9130 |
| 21 Apr 2022 | $0.9130 |
| 20 Jan 2022 | $0.8700 |
Amounts are as declared and are not adjusted for withholding tax. Dividend policy can change at any time.
| Period | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| 2026-09-30 · Q1 2027 | 1.94 | 2.00 | +3.09% |
| 2026-06-30 · Q4 2026 | 1.45 | 1.43 | -1.47% |
| 2026-03-31 · Q3 2026 | 1.60 | 1.59 | -0.77% |
| 2025-12-31 · Q2 2026 | 1.91 | 1.88 | -1.63% |
Estimates are consensus figures collected by the data provider. Reported values can be restated after publication.
Berkshire Hathaway, JPMorgan and Procter & Gamble benefit from strong business fundamentals, but rising costs and growth challenges create risks.
Read more
When recessions hit, some companies keep raising the check anyway. Three consumer giants and one regulated utility did it through 2008 and 2020, yet each c...
Read more
A million dollars sounds like plenty until you need it to pay you every month. Five blue chips across five sectors split the load, but one of them carries...
Read more
Today's big story: Could Anthropic Stock Fall 25.
Read more
PG raises its sales outlook following the Thorne acquisition, but unchanged organic growth guidance, rising financing costs and restructuring risks temper...
Read more
PG's improving organic sales, stronger volumes and healthy cash flow support growth, but premium valuation and rising costs warrant a cautious stance.
Read more
Kimberly-Clark's Kenvue acquisition targets $2.1 billion in annual synergies, expanding its earnings potential, but integration costs and dilution pose nea...
Read more
Kimberly-Clark's discounted valuation and productivity gains offer support, but weak demand, earnings pressure and Kenvue integration risks favor a cautiou...
Read more
PG's broad-based organic growth, strong segment performance and productivity gains fuel momentum, but cost pressures and premium valuation pose challenges.
Read more
Clorox keeps raising its dividend, but the cash behind it tells a different story. With new debt, a downgrade, and a leadership handoff looming, one number...
Read moreHeadlines and summaries are supplied by third-party news providers. Links open the original publisher. Inclusion does not imply endorsement.
Add the app to your home screen for faster access to market data.
Use Google Chrome on your Android phone or tablet. Other Chromium browsers such as Edge or Samsung Internet work too.
Tap the three-dot menu in the top-right corner of the browser.
Select Install app or Add to Home screen from the menu.
Tap Install in the prompt. The Expert Options View icon appears on your home screen and app drawer.
On iPhone or iPad, installation only works in Safari. Open this page in Safari rather than Chrome or Firefox.
Tap the Share icon in the toolbar at the bottom of the screen.
Swipe down the share sheet and tap Add to Home Screen.
Confirm with Add in the top-right corner. The app icon is added to your home screen and opens full screen.
The app is free, takes no extra storage beyond a small cache, and works on Android and iOS. No app store account is needed.